Key Findings

🧬 GLP-1 Deficiency Makes Organ Transplant Rejection Worse

Researchers discovered that mice lacking GLP-1 receptors had dramatically higher rates of bone marrow transplant failure when receiving mismatched donor cells. The GLP-1-deficient mice experienced greater weight loss, earlier death, and reduced donor cell survival compared to normal mice. When scientists removed the recipient's T cells before transplant, the GLP-1-deficient mice recovered normal transplant success rates.

📊 Tirzepatide Slashes 10-Year Disease Risk Predictions

In a 3-year study of people with obesity and prediabetes, tirzepatide dramatically reduced predicted cardiovascular and diabetes risk. The 15mg dose lowered 10-year heart disease risk by 9.2% using standard prediction tools, while placebo users saw their risk increase by 57.9%. For diabetes risk, all tirzepatide doses reduced 10-year risk by about 19%, compared to just 4.3% reduction with placebo.

🎯 GLP-1 Drugs Show Promise for Skin Conditions

A systematic review found that GLP-1 receptor agonists improved various skin conditions including psoriasis, hidradenitis suppurativa, acne-related hair loss, and insulin resistance-related skin darkening. The improvements appeared to work through multiple pathways: reducing inflammation, improving metabolism, and strengthening skin barrier function.

💡 Genetic Variants Predict Who Responds Best to GLP-1 Drugs

In a small Bulgarian study of 27 people with type 2 diabetes, genetic variants in the GLP-1 receptor and drug transporter genes influenced treatment response. People with certain OCT1 gene variants had different cholesterol responses to metformin, while GLP-1 receptor variants showed trends for affecting weight loss with semaglutide (though this didn't reach statistical significance in the small study).

🧪 GLP-1 Drugs Change Gut Bacteria in Youth with Diabetes

In African American youth with type 2 diabetes, metformin alone increased beneficial bacteria like Eubacterium (which produce helpful compounds), while metformin plus liraglutide increased different beneficial bacteria like Bacteroides fragilis. Metformin users had higher levels of secondary bile acids in their blood, and one specific bile acid (nutriacholic acid) correlated with better blood sugar control.

⚠️ Rare Cases Link GLP-1 Drugs to Autoimmune Pancreatitis

Doctors reported 3 cases of type 1 autoimmune pancreatitis (a rare immune attack on the pancreas) in people taking GLP-1 agonists for diabetes. The researchers hypothesize that GLP-1-induced pancreatic growth might alter immune responses in susceptible individuals, potentially triggering this autoimmune condition.